A-375

A-375 (Melanoma CDX Model)

The A-375 melanoma cell line was established from a female patient with malignant melanoma. It carries the BRAF V600E mutation, a key driver of melanoma progression. This mutation makes A-375 one of the most widely used preclinical models for targeted therapy studies. Its defined genetics provide a strong foundation for precision oncology research.

Key Features: 

• Derived from malignant melanoma of the skin. 

• Contains BRAF V600E mutation. 

• Strong MAPK pathway activation. 

• Well suited to targeted therapy studies. 

Applications: 
A-375 is applied in studies of BRAF and MEK inhibitor response. It is also used in immuno-oncology and combination therapy evaluation. Researchers employ this model to investigate MAPK pathway biology and drug resistance. Its reproducibility makes it a benchmark system in melanoma research.